ESMO Highlights

Rucaparib Maintenance Extends Survival in Platinum-Sensitive Ovarian Cancer

Phoebe Starr

November 2017, Vol 7, No 11 - ESMO Highlights, Ovarian Cancer

Madrid, Spain—Maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor rucaparib (Rubraca) after response to platinum-containing therapy significantly improved progression-free survival (PFS) by 11.2 months in patients with recurrent ovarian cancer compared with placebo, according to overall results of the ARIEL3 trial. The study was presented at the 2017 European Society for Medical Oncology (ESMO) Congress. [ Read More ]

Practice-Changing: Nivolumab plus Ipilimumab Beat Sunitinib as First-Line Treatment for Metastatic RCC

Phoebe Starr

November 2017, Vol 7, No 11 - ESMO Highlights, Renal-Cell Carcinoma

Madrid, Spain—The combination of nivolumab (Opdivo) plus ipilimu­mab (Yervoy) improved overall response rates (ORRs), progression-free survival (PFS), and overall survival (OS) in patients with intermediate- and poor-risk metastatic renal-cell carcinoma (RCC) compared with sunitinib in the CheckMate-214 study. These results were presented at the 2017 European Society for Medical Oncology Congress. [ Read More ]

Regular CT Scans for NSCLC Follow-Up May Not Be Necessary

Phoebe Starr

November 2017, Vol 7, No 11 - ESMO Highlights, Lung Cancer

Madrid, Spain—Findings from a randomized clinical trial suggest that follow-up computed tomography (CT) scans in patients with fully resected non–small-cell lung cancer (NSCLC) may not be needed every 3 to 6 months in the first 2 years after surgery. Results of the IFCT-0302 study were presented at the 2017 European Society for Medical Oncology (ESMO) Congress, showing no significant difference in overall survival (OS) among patients who had CT scans as part of their follow-up versus those who did not. [ Read More ]